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In vitro and in vivo effects of toceranib phosphate in canine osteosarcoma cell lines 
and xenograft orthotopic models
Abstract 
Canine osteosarcoma (OSA) is the most common primary malignant bone tumour with a 
high metastatic rate and poor prognosis. Toceranib phosphate (TOC) (Palladia®, Zoetis, 
U.S.A.) is a veterinary tyrosine kinase inhibitor (TKI) that selectively inhibits VEGFR-2, 
PDGFRs and c-Kit, but its efficacy in canine OSA is not fully understood. Here, we 
evaluated the functional effects of TOC on six OSA cell lines by transwell, wound healing 
and colony formation assays. Subsequently, two cell lines (Wall and Penny) were selected 
and inoculated in mice by intra-femur injection, developing an orthotopic xenograft model 
of canine OSA. For each cell line, 30 mice were injected, half of them used as control and 
the other half treated with TOC at 40 mg/kg body weight for 20 days; then mice were 
sacrificed and subjected to necroscopy. TOC inhibited cellular growth in all the cell lines 
and reduced invasion and migration in Penny and Wall cell lines. Significantly, TOC 
treatment decreased tumour growth only in mice inoculated with Penny. Moreover, specific 
transcripts of PDGFRs and c-Kit resulted down-regulated in these tumours. 
Immunohistochemical studies demonstrated a significant reduction of Ki67 in treated mice 
when compared to controls. Results obtained demonstrated that TOC is able to slightly 
inhibit cell growth in vitro, while its effect is evident only in Penny’s xenograft model, where 
TOC significantly reduced tumour dimension and proliferating index without modifying 
apoptosis markers and mitotic index. These data may open a new scenario in canine OSA 
treatment and patient selection based on TKI targets expression.
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Introduction
Considering the high similarity at clinical, histopathological and molecular level, 
spontaneous tumours in dog are considered potential models for human diseases, 
representing an alternative to rodents for studying cancer biology and therapy1,2. Canine 
osteosarcoma (OSA) represents the most common primary malignant bone tumour, 
accounting for more than 80% of all bone tumours, being locally aggressive, and 
characterized by a high metastatic potential and poor prognosis1,3,4. Furthermore, the role 
of several tyrosine kinases receptors (TKRs) in the pathogenesis of canine OSA has 
recently been demonstrated 5-7, as well as the opportunity to use tyrosine kinase inhibitors 
(TKI) against specific targets8,9. 
TKI have radically changed the treatment approach and prognosis in several human 
tumours 10,11; also in veterinary medicine this class of molecules resulted promising in few 
cancer histotypes 12-15. Toceranib phosphate (TOC) (Palladia®, Zoetis, U.S.A) is a specific 
veterinary TKI that selectively inhibits VEGFR-2, PDGFRs and c-Kit and is currently 
approved for treatment of mast cell tumours16,17. However, there is increasing evidence 
that other solid tumours such as anal sac, head-neck and thyroid carcinomas, and OSA 
can be successfully treated with TOC18-19. Although, a recent clinical trial showed 
controversial results when using Palladia® as a single agent in canine metastatic OSA20. 
Xenograft mouse models represent important tools to investigate the in vivo 
response to cancer therapeutic interventions. Previously published canine OSA mouse 
models were heterotopic and obtained implanting OSA cells intramuscularly (IM) or 
subcutaneously (SC)21-23, however intrinsic limitations were evident such as OSA cells 
were not exposed to the constitutive microenvironment. Consequently, the biological 
behaviour of the xenograft tumour and its response to therapy might have not completely 
reflected the disease progress. Orthotopic mouse models represent a more reliable 
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approach to evaluate tumour progression and pharmacological treatment efficacy. As 
mentioned previously , the clinical use of TOC in canine OSA is still scientifically argued 
and further investigations are needed. Considering the relevance of canine OSA both in 
veterinary medicine and comparative oncology, the aims of this study were to evaluate the 
functional effects of TOC in primary OSA cell lines and to develop orthotopic mice models 
of canine OSA. In addition, mRNA and protein changes of the preferential targets of TOC, 
as well as the clinical response, were also evaluated in vivo.
Material and Methods
Cell lines and cell culture
Seven primary canine OSA cell lines ("Penny", "Wall", "Desmond", "Sky", "Dark", 
"Lord" and "Pedro"), previously established by Maniscalco et al. (2013)6, were used in this 
study. All cell lines were maintained in Iscove´s standard medium supplemented with 10% 
foetal bovine serum (FBS), 1% glutamine, 100 µg/mL penicillin and 100 µg/mL 
streptomycin, cultured at 37°C in a humidified atmosphere of 5% CO2, and passaged upon 
reaching confluence. A normal osteoblastic cell line (OSB) was isolated from a healthy dog 
using a procedure described before5.
Transwell assay
The migration capability of the OSA cell lines was evaluated as follows. Cells were 
trypsinized, resuspended in Iscove´s standard medium and counted in Bürker chambers. 
Subsequently, 1.5 X 104 cells were resuspended in 200 µl of supplemented Iscove´s 
standard medium and added to the non-coated upper chamber of a transwell with 8 µm 
pore size filter (Corning Coster, Cambridge, MA, USA). To test the effects of TOC on the 
migratory capability of canine OSA cell lines, 800 µl of supplemented Iscove´s standard 
medium with 1 µM of TOC was added to the lower chamber (treated groups) of the wells. 
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For controls, 800 µl supplemented Iscove´s standard medium without TOC was added. 
After 48 hours incubation, cells on the upper side of the filter were mechanically removed 
with a cotton swab, and both cells migrated to the lower side of the transwell and those 
that reached the bottom of the wells were incubated with 5 µg/mL Hoechst 33342 (Sigma 
Diagnostic, St Louis, MO, USA) in 1 mL culture medium at 37°C under 5% CO2 for 20 
minutes, rinsed with PBS (Phosphate Buffer Solution) for 10 minutes 3 times. Both the 
filter and the bottom of the wells were photographed with a fluorescent equipped 
microscope at 100x and cells were counted using ImageJ software. Analysis was run in 
triplicate.
Wound healing assay
Considering the results obtained by transwell assay, Penny and Wall cell lines were 
selected for the mobility assay. After trypsinization, 2 x 105 cells/well were plated in a 6-
wells plates to grow. When the confluenc  was reached, the monolayer was wounded by 
applying a manual scratch and using a sterile 20 µL pipette tip. The cellular debris was 
removed with a gentle wash with complete medium and the supplemented Iscove´s 
medium with 1 µM of TOC (treated groups) or without TOC (control groups) was added to 
the cells. The ability of the cells to repair the wound was evaluated by real time microscopy 
for 48 hours. Cell migration was monitored using a Leica AF6000 LX (Leica Microsystems, 
Wetzlar, Germany) inverted microscope equipped with a Leica DFC350FX digital camera 
and the photographs were taken every 30 minutes for 48 hours. The distance between two 
parallel lines was measured in 5 different areas along the length of the wound and the 
analysis was run in duplicate. 
Colony formation assay
Penny and Wall were resuspended in 0.4% type VII low melting agarose in DMEM 
(10% FBS) at 2 X 104 cells/well, plated on a layer of 0.8% agarose in Iscove´s medium 
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(10% FBS) in 6-well culture plates and cultured at 37°C with 5% CO2. After 24 hours, the 
medium was removed and replenished with fresh medium with 1 µM of TOC (treated 
groups) or without TOC (control groups). The medium was changed every 3 days and after 
3 weeks, colonies >100 µm and <100µm in diameter were counted with an inverted phase-
contrast microscope. Colony formation assays were repeated in triplicates.
Cell growth assay
Penny and Wall cell lines were plated in 6-well plates and grown until 90% of 
confluence (highly proliferating), then detached and counted in a Bürker chamber. A total 
of 3000 cells were seeded in 6-well plates till attachment at a maximum of 6 hours, and 
TOC was added to the treated wells at 1µM concentration. After 72 hours, cells were 
rinsed with PBS and incubated with 5 µg/mL Hoechst 33342 (Sigma Diagnostic, St Louis, 
MO, USA) in 1 mL culture medium at 37 ºC under 5% CO2 for 20 minutes. Cells were then 
rinsed again with PBS, observed under a fluorescent microscope at 100x and nuclei were 
counted using ImageJ software.
Orthotopic xenograft mouse model
 A total of 60 female nu/nu mice, 4–5 week-old, purchased by Charles River 
Laboratories (Calco, Milan) were housed under pathogen free condition with a 12h 
light/12h dark schedule, fed autoclaved standard chow and water ad libitum. Mice were 
manipulated and housed according to protocols approved by the XXX University Bioethical 
Committee and the Italian Ministry of Health (Authorization receipt n. 149401894128). For 
the intra-femur injections, exponentially growing cells (Penny and Wall) were harvested, 
counted and resuspended in PBS to a final concentration of 1 X 107 cells/ml. The animals 
were anesthetized with zolazepam/tiletamine (45 mg/kg) and xylazine (7.5 mg/kg). The 
knee of the mouse was fixed beyond 90° and 1 X 106 cells resuspended in 100 µl of PBS 
were injected into the distal femur using a 25-gauge needle. On day 0, 30 mice were 
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injected using Penny and  Wall, respectively. Twice a week, mice were monitored to 
determine the appearance and/or clinical signs of the engrafted tumour. When an average 
tumour size of 0.5 cm in the largest diameter was obtained, daily treatment with TOC or 
vehicle was initiated. Mice were randomly assigned into each group. According to 
literature, mice were administered once daily with TOC at 40 mg/kg body weight in citrate 
buffered (pH 3.5) solution 24,25 for 20 days by oral gavage using rigid dosing cannula. 
Control mice were treated only with citrate buffered saline administered with the same 
procedure. Tumour growth was evaluated twice a week by measuring the tumour size by a 
caliper. Tumour length (L) and width (W) were measured to calculate tumour volume (V) 
as follows: (L x W2)/2. Contextually, body weight was also measured. Five mice were not 
inoculated and used as body weight control.
Mice were checked up to 20 days post-treatment or till animal endpoint criteria were 
reached (ill thrift, visible lameness, pain or severe weight loss), then they were humanely 
euthanized by an intravenous overdose injection of sodium pentobarbital. At post-mortem 
examination the tumours were excised and cut into two pieces to be frozen in liquid 
nitrogen for RNA extraction and fixed in 10% neutral buffered formalin for routine 
histological exam and immunohistochemistry.
RNA extraction and quantitative reverse transcription PCR (RT-qPCR) expression analysis
Total RNA from all the OSA cell lines and OSB, as well as from engrafted tumours, 
was extracted using 1ml of TRIReagent (Sigma-Aldrich) and any residual genomic DNA 
was removed using a DNAse I Recombinant RNAse free kit (Roche, Mannheim, 
Germany). RNA concentration was determined by spectrophotometry (BioPhotometer, 
Eppendorf, Hamburg, Germany). The ratio of the optical densities measured at 260 and 
280 nm was >1.9 for all RNA samples. cDNA was synthesized from 1 µg of total RNA by 
RT High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, 
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USA), according to the manufacturer’s protocol. To determine the relative amounts of 
specific PDGFRα, PDGFRβ, VEGFR2 and c-Kit transcripts, RT-qPCR was performed 
using the CFX Connect Real-Time PCR System (Bio-Rad, Hercules, CA, USA). Primers 
for target and reference genes were designed on Canis Familiaris GenBank messenger 
RNA (mRNA) sequences using Primer 3 Software (version 4.0). Oligonucleotides were 
designed to cross the exon/exon boundaries to minimize the amplification of contaminant 
genomic DNA and were analyzed using the IDT tool (available at 
http://www.idtdna.com/scitools/scitools.aspx) for hairpin structure and dimer formation. 
Primer specificity was verified with BLAST analysis against the genomic NCBI database. 
Multiple housekeeping genes were selected among 5 potential internal control mRNAs in 
the dog (HPRT, GAPDH, RP13a, RP18s and RP32) and on the basis of efficiency value 
GAPDH was selected as the most suitable for the purpose.
Supplementary Table 1 summarizes the primer information, sequences, gene accession 
number and amplicon sizes. Real-time PCR parameters were: cycle 1, 95°C for 30 s; cycle 
2, 95°C for 10 s, 60°C for 30 s for 40 cycles. Gene Expression was calculated using the 
formula of 2-ΔΔCq (fold increase), where ΔΔCq= ΔCq (target) – ΔCq (control) and ΔCq is 
the Cq of the target gene subtracted from the Cq of the housekeeping gene.
Histopathological and Immunohistochemical analysis
Systemic organs and tumours obtained from mice were fixed in 10% buffered 
formalin for 24 hours. When needed, tumours were decalcified in 10% formic acid, and 
procedures for histological examination were applied. Also, several histological parameters 
were selected and scored (see Supplementary Table 2).
Immunohistochemistry (IHC) was performed on 4 μm thick paraffin sections derived 
from OSA originated in mice using an automated immunostainer (DAKO). After blocking 
peroxidase activity and heat-induced antigen retrieval, sections were incubated with Ki67, 
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c-Kit and caspase 3 antibodies (see supplementary Table 3). Positive immunostaining for 
Ki67 was determined by counting 1000 cells in 10 high power randomly-selected 
neighbouring, non-overlapping fields. The number of Ki67-positive and negative cells was 
assessed by image analysis using ImageJ freeware and the number of positive cells was 
expressed as the percentage of positively stained cells in the total number of cells26. 
Immunohistochemical evaluation of caspase 3 was carried out by taking images at x40 
microscope objective from 10 random fields per tumour, to provide an average index of 
caspase 3 positive cells27. For the IHC evaluation of c-Kit expression, the specimens were 
scored according to both the percentage of positively stained tumour cells and their 
immunostaining intensity28.
Statistical analysis
IHC results were grouped into contingency tables and analyzed using Fisher’s exact 
test or X2 test while q-PCR and in vitro data assays were analyzed using Student’s t test. 
Data were analyzed using MedCalc Statistical Software version 13.3 (MedCalc Software 
bvba). A p value lower than 0.05 was considered statistically significant.
Results
TOC inhibits OSA cell migration in vitro
The effect of TOC on OSA cells migration was assessed by transwell migration and 
wound healing assays. All the canine OSA cell lines showed the ability to migrate through 
the membrane and to attach to the lower side. Few cells detached and reached the bottom 
of the wells. Conversely, TOC treatment reduced OSA cell migration to the bottom of the 
membrane, within a range from 26.5±11.6% (Penny) to 88.1±1.1% (Sky; Fig. 1a). 
Inhibition of cells attachment by TOC ranged from 32±0.9% (Wall) to 93±15.7% (Lady; Fig. 
1b). Representative images of Hoescht stained nuclei in untreated controls and TOC 
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treated cells are shown in Figure 1c. Wound healing assay showed a similar inhibitory 
effect in TOC treated OS cell lines (Supplementary Video 1). The migration rate was 
decreased to 43.9± 24.8% in Penny (Fig. 2a) and 71.0±14.3% in Wall (Fig. 2b). 
Considering these preliminary results, Penny and Wall were selected for the following in 
vitro and in vivo experiments.
TOC inhibits cell growth and anchorage-independent OSA cell growth in vitro
To assess the growth effect of TOC, Penny and Wall were exposed to TOC for 72 
hours. TOC treatment reduced cell growth by 14.6±2.5% and 32.16±4.2% in Penny and 
Wall, respectively. To investigate OSA cells growth on anchorage-independent conditions, 
a colony formation assay was performed. Both cell lines formed colonies when grown 
resuspended in agarose, but TOC treatment in Penny and Wall slightly decreased colony 
numbers compared to untreated cells (Fig. 3a). Thereby, when considering exclusively the 
colonies >100 µm in diameter, TOC tr atment showed a higher inhibition of colony 
formation, with a reduction of 37.7±8.0% for Penny and 85.7±12.0% for Wall (Fig. 3b).
TOC reduces in vivo tumour growth only in Penny xenograft model
To evaluate the activity of TOC in vivo, we generated two orthotopic xenograft 
mouse models using Penny and Wall. Both cell lines were tumorigenic and primary 
tumours were macroscopically visible 18 days after injection in 85% of mice (n=51) with a 
volume of approximately 3-4 mm3. TOC treatment was started at 22 days post-inoculation 
and finished at day 42. The experimental design and the time lines of the treatment are 
shown in Figure 4a. Six mice engrafted with Penny (20%) and 3 mice engrafted with Wall 
(10%) didn’t develop tumours at any time, also confirmed at necropsy. Drug-related side 
effects were observed after 3-4 days of treatment including dermatitis in 5 (33.3%) and 4 
(26.7%) mice inoculated with Penny and Wall, respectively. However, TOC significantly 
decreased tumour growth in mice inoculated with Penny, but not with Wall cell line (Fig. 
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4b). Also, no differences in body weight between the four different groups were evident 
(Fig. 4c).
TOC treatment reduces PDGFRα, PDGFRβ, VEGFR2 and c-Kit mRNA expression in 
both in vivo and in vitro models
Quantitative RT-PCR results (Fig. 5a) revealed that all the OSA cell lines had a 
higher mRNA expression of both PDGFRα and PDGFRβ compared to the OSB control cell 
line (P<0,05). The only exception was Dark cell line for PDGFRα. VEGFR2 and c-Kit 
mRNAs were increased in 3 out of 7 OS cell lines (Penny, Wall and Lord) when compared 
to the OSB cell lines (P<0,05). Finally, we examined PDGFRα, PDGFRβ, VEGFR2 and c-
Kit mRNA expression in tumours obtained from TOC treated and control mice. A 
significant down regulation of PDGFRα, PDGFRβ and c-Kit in mice inoculated with Penny 
and treated with TOC compared to controls was found, confirming in vitro results (Fig. 5b), 
whereas no differences were retrieved in mice inoculated with Wall (Fig. 5b).
TOC treatment influences tumour cell density and KI-67 score
Histological examination of the xenograft tumors confirmed a chondroblastic OSA 
from Penny (Fig. 6A) and osteoblastic productive OSA (Fig. 6B) from Wall7 . No 
differences for anisocytosis, anisokaryosis, presence of haemorrhages, vascular invasion, 
bone marrow invasion or muscular invasion were found after treatment. Notably, the grade 
of anisocytosis and anisokaryosis was always elevated (Fig. 6C) in association with 
necrotic-haemorrhagic areas (Fig. 6D). Conversely, bone marrow invasion occurred in 
12/51 tumours (23%) (Fig. 6E); muscular invasion in 48/51 samples (93%) (Fig. 6F), but 
no differences were found between the two groups. Of note, in the only mouse of the study 
(belonging to the Wall control group) in which vascular invasion was diagnosed, presence 
of lung metastasis was also observed (Fig.6G).
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Histologically, TOC-treated Penny and Wall xenograft models had a decrease of tumour 
cell density when compared to vehicle-treated animals (p=0.015 and p=0.03, respectively). 
Although the differences were not significant, a trend towards a decrease in the amount of 
matrix and necrosis  was observed after TOC treatment both in tumours originated from 
Penny and Wall. By immunohistochemistry, tumours from TOC treated mice showed a 
lower Ki-67 score (Fig.6H) when compared to tumours grown in vehicle-treated mice 
(Fig.6I). Also, a significant reduction of cellular density was obtained both in Penny and 
Wall engrafted tumours (p<0.005). Conversely, Caspase 3 expression was not influenced 
by TOC treatment.
Discussion
OSA represents the most common primary malignant bone tumour in dog, with a 
high metastatic potential and poor prognosis1,29. In humans, this disease is still scarcely 
curable with a high rate of metastasis.30,31 Comparative oncology studies have shown 
many similarities between OSA occurring in human and canine patients, and also in 
veterinary oncology the development of xenograft models32 in mice represents nowadays 
an important alternative to investigate the microenvironment and the molecular 
mechanisms driving cancer growth, as well as to evaluate the biological effects of novel 
therapeutic agents such as TKIs.
In our study, we developed an orthotopic model of canine OSA and further tested 
the biological and pharmacological effects of TOC. To identify the most promising cell line, 
TKRs targets of TOC were firstly evaluated by RT-qPCR in seven canine OS cell lines. All 
of them showed an heterogenous amount of mRNA that was gene dependent. 
Interestingly, similar variations were previously described when considering protein6,33,34.
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Cell lines were further investigated by several biological assays in order to 
determine whether cell migration was affected by treatment with TOC. Transwell assay 
demonstrated that all the OSA cell lines were able to migrate in absence of chemo-
attractive factors; conversely migration was negatively affected by TOC, although to a 
different extent among cell lines. Interestingly, Penny and Dark resulted the most sensitive 
to TOC treatment using the proliferating assay, while the migration score was the highest 
in Penny and the lowest in Wall. Wound healing migration rate, colony formation and cell 
growth rate in soft agar assays revealed that both Penny and Wall were negatively 
affected by TOC treatment. Overall, these in vitro results suggested that Wall and Penny 
responded to TOC treatment by slightly reducing their migration and proliferating 
behaviour. This might be due to the ability of TOC to inhibit the kinase activity of the target 
receptors and consequently the downstream activated pathways, as demonstrated in 
previous results obtained by other authors where AG1296 induced down regulation of p-
AKT in time and dose dependence 6,35,36.
To validate the in vitro results, both Penny and Wall cell lines were inoculated in an 
orthotopic model, and the cellular growth of OSA was monitored. Results demonstrated 
that both Penny and Wall cells were highly tumorigenic, showing engraftment after 18 
days. Also, tumour histology confirmed that both cell lines conserved the original 
morphological features. Interestingly, TOC treatment decreased the tumour growth in mice 
inoculated with Penny but not with Wall. Regarding the selected histological parameters, 
tumour cell density was reduced in treated mice compared to control mice independently 
from the cell line origin. It is worth noting that vascular invasion as well as lung metastasis 
was reported only in one mouse from Wall control group. This observation, even with 
several limitations, suggests a possible inhibitory effect on the metastatic spread by TOC 
as shown in the metastatic DARK cell line that resulted more sensitive to the TOC 
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treatment. Unfortunately, this observation cannot be confirmed statistically due to the low 
number of occurrences. With regard to this aspect, it could be speculated that the 
metastatic process is mediated by the microenvironment that develops within the 
orthotopic model and that possibly depends on VEGFR2 expression, as recently 
demonstrated in human OSA37. No mRNA expression modifications for PDGFRs, 
VEGFR2 and c-Kit were found in tumours removed from control versus TOC-treated mice, 
implying that TOC treatment did not act at the transcriptional level of these genes.
Ki67 results demonstrated a lower proliferation index (PI) in TOC treated tumours 
than in the ones of control mice (in both Penny and Wall groups). This data indicate a TOC 
effect in decreasing tumour proliferation, but not on cell apoptosis, as shown by caspase-3 
results. Interestingly, Sunitinib (SU11248) is the equivalent of TOC in humans being 
administered in patients with gastrointestinal stromal tumours (GIST), neuroendocrine 
tumours and renal carcinomas, while is off-label in human OSA38 and recently it was 
tested in xenograft models of human OSA cell lines showing an evident reduction of the 
tumour growth and PI, thereby mimicking our results39.
Today, clear indications for using TOC in canine OS treatment are not available, 
and recent clinical trials do not support the use of TOC as a single agent therapy for 
canine metastatic OS20,40. Moreover, the use of TOC in c-Kit mutated mast cell tumours 
was also recently discussed41. Our results demonstrate that TOC is able to inhibit cell 
growth in vitro only mildly, while its effect is more relevant in xenograft models.  
Considering the relevant expression of PDGFRs, c-Kit and VEGFR2 in Penny, these data 
suggest that TOC treatment might be more effective in tumours expressing these targets. 
Further studies are needed to test the efficacy of this molecule in canine OSA, but these 
results open a new scenario where only a subset of OS having high target levels might 
respond to TOC treatment. 
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LEGENDS TO FIGURES 
Figure 1.
Cellular migration by transwell assay. (A) Percentage of cells attached to the lower side of 
the membrane and (B) the bottom of the lower chamber in all canine OSA cell lines treated 
with Toceranib (1μM) compared to the control (untreated). Error bars represent standard 
deviation of experimental triplicates. (C) Immunofluorescence assay showing cells 
migrated to the bottom of the lower chamber in Sky and Wall cell lines treated with TOC 
compared to the untreated cell lines (Hoescht staining) (200x, Scale bar= 250μm). 
Figure 2.
Wound Healing Migration Assay.  Penny cell line (A) and Wall cell line (B) after 48h of 
treatment with TOC (1 μM) with respectively not treated cell lines. (400x, Scale bar= 
100μm). 
Figure 3.  
Colony Formation Assay. (A) Percentage of colonies formed in agarose in Penny and Wall 
cell lines treated with TOC 1μM compared to the untreated cells. (B) Percentage of 
colonies (>100μm diameter) formed in agarose in Penny and Wall cell lines treated with 
TOC 1μM.  Error bars represent standard deviation of experimental triplicates.
Figure 4. 
Experimental Xenograft Design. (A) Experimental timeline of OSA xenograft on mice and 
TOC treatment. (B) Measurements of tumour volume of xenografts of Wall or Penny cell 
lines in mice, along the treatment with TOC and with a vehicle (from T0 to T0+21days). As 
shown in the figure mice inoculated with Penny cells and treated with TOC showed a 
significant smaller tumour volume compared to those treated with a vehicle (*p<0.05). (C) 
Weight of mice with Wall or Penny xenografts, treated with TOC or with vehicle, at the end 
of the experiment. No variation between the groups is highlighted. 
Figure 5. 
Quantitative PCR. (A) Expression of PDGFR-α, PDGFR-β, VEGFR-2 and c-Kit transcripts 
in primary osteosarcoma (OSA) cell lines. PDGFR-α mRNA were expressed at higher 
levels in 7/7 OSA cell lines, PDGFR-β in 4/7, VEGFR-A transcript had a higher expression 
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in 4/7 OSA cell lines and c-Kit in 2/7, compared to the normal cell line (OSB) (*p<0.05). 
The fold increase of each specific mRNA was normalised with normal OSB cell line and 
the error bars indicate the standard deviation of experimental triplicates. (B) Expression by 
quantitative PCR of PDGFR-α, PDGFR-β, VEGFR-2 and c-Kit in primary Wall and Penny 
OS cell lines treated with TOC, compared to the control (untreated). Wall cell line showed 
a lower expression of PDGFR-α, PDGFR-β and c-Kit when treated (*p<0.05). Penny cell 
did not show any significant variation. The fold increase of each specific mRNA was 
normalised with the control cell line and the error bars indicate the standard deviation of 
experimental triplicates.
Figure 6. 
Histological features of osteosarcoma xenografts. (A) Penny cell line xenograft showing  
chondroblastic. Neoplastic cells have a chondrocyte-like morphology and are located 
within lacunae. H&E stain (400x, bar= 50 μm). (B) Wall cell line xenograft showing, 
osteoblastic hystotype Neoplastic cells surrounded by irregular trabeculae of osteoid 
matrix. H&E stain (400x, bar= 50 μm) and (C) Marked anisocytosis and anisokaryosis. (D) 
Necrosis involving the 30% of the neoplastic tissue. (200x, scale bar= 100μm). (E) Bone 
marrow invasion (200x, scale bar= 100μm). (F) Muscular invasion (200x, scale bar= 
100μm). (G) Pulmonary Metastasis (200x, scale bar= 100μm). Nuclear Ki-67 
immunolabelling respectively in Penny xenograft (H) treated with TOC and not treated 
mice (I). Streptavidin–biotin–peroxidase method. Mayer’s haematoxylin counterstain 
(400x, bar= 50 μm). 
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Tumour cell density2 1= <25% of cells
2= 25-50% of cells
3= 50-75% of cells
4= >75% of cells
Mitotic Index1 Number of mitosis in 10 high-power fields (400x)
Amount of matrix2 1= >50% matrix
2= 25-50% matrix
3= <25% matrix
Amount of necrosis1 0= no necrosis
1= <25% of necrosis
2= 15-50% of necrosis
3= >59% of necrosis
Haemorrage 0= absence of haemorrage
1= presence of haemorrage
Invasion of the bone 0= absence of invasion
1= bone invasion
Invasion of the bone marrow 0= absence of invasion
1= bone marrow invasion
Invasion of the muscle 0= absence of invasion
1= muscle invasion
1. Kruse MA, Holmes ES, Balko JA, Fernandez S, Brown DC, Goldschmidt MH. Evaluation of clinical and 
histopathologic prognostic factors for survival in canine osteosarcoma of the extracranial flat and 
irregular bones. Vet Pathol. 2013;50(4):704-708.
2. Kirpensteijn J, Kik M, Rutteman GR, Teske E. Prognostic significance of a new histologic grading 
system for canine osteosarcoma. Vet Pathol. 2002;39(2):240-246.
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Table 1.
Antibodies used in immunohistochemistry
Antibody Type Source Concentration
Ki67 Mouse monoclonal Dako, Burlingame, CA, USA 1:75
Caspase-3 Rabbit polyclonal R&D systems, Minneapolis, MN, USA 1:250
c-Kit Rabbit polyclonal Dako, Burlingame, CA, USA 1:750
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